Head-to-head · Cost-Efficiency Index
VevaRX vs Bliv
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
VevaRX
Readers in one of the 36 states it names who will confirm the charge in writing before submitting an intake.
Visit VevaRXBliv
Cost-first shoppers who want mainstream telehealth GLP-1 access.
Visit BlivThe verdict
VevaRX takes it, leading the Cost-Efficiency Index 60 to 59. VevaRX sells compounded semaglutide at $189 a month and tirzepatide only as a $467 quarterly plan with a three-month minimum, on a site that prints at least eight mutually contradictory prices for its own products. Bliv still earns a C — Cost-first shoppers who want mainstream telehealth GLP-1 access.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs VevaRX.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | VevaRX | Bliv |
|---|---|---|
| Cost-Efficiency Index | 60/100 | 59/100 |
| Semaglutide / mo | $189/month month-to-month (the same page also prints $167/month and a $467 three-month total) | $116/mo (as low as, varies by plan and eligibility, compounded) |
| Tirzepatide / mo | $155.67/mo equivalent — VevaRX bills $467 every three months on a three-month minimum and publishes no monthly plan | $199/mo (as low as, varies by plan and eligibility, compounded) |
| Semaglutide / yr (modeled) | $2,268 | $1,392 |
| Tirzepatide / yr (modeled) | $1,860 | $2,388 |
| Coverage | 36 states | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #261 | #264 |
VevaRX
60/100Where the value is
- Enumerates the 36 states it serves by name rather than making an unqualified nationwide claim
- States what the tirzepatide price covers — the treatment, the supplies, the provider visit and two-to-three-day shipping
- Publishes a monthly semaglutide option alongside the quarterly plan, which its tirzepatide program does not offer
The tradeoffs
- The semaglutide page carries four prices, two of which belong to tirzepatide: $189 a month, $399 for three months, $167 a month and a $467 total
- The tirzepatide page's own arithmetic is wrong — it calls $467 over three months "equivalent to $149 per month", when it is $155.67, a figure the semaglutide page states correctly
Bliv
59/100Where the value is
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
The tradeoffs
- The advertised rates are 'as low as' figures footnoted 'based on plan structure and eligibility', and the plan selector sits behind the medical intake — the rate you are offered is not knowable before you hand over a medical history
- A $24.99 provider consultation fee is charged on top, and the refund policy deducts $200 for 'clinical coordination and account setup'
Regulatory note: the FDA issued a warning letter to Bliv Wellness LLC dba Bliv in February 2026. We still list and link to Bliv; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.